Stock Events

Bluebird bio 

M$57.5
0
+M$0+0% Friday 18:11

Statistics

Day High
57.5
Day Low
57.5
52W High
152.21
52W Low
54
Volume
35
Avg. Volume
0
Mkt Cap
12.92B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27MarExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q2 2023
Q3 2023
Next
-1.66
-1.25
-0.85
-0.44
Expected EPS
-0.62
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BLUE.MX. It's not an investment recommendation.

About

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Andrew Obenshain
Employees
518
Country
United States
ISIN
US09609G1004

Listings